Multiple MYO18A-PDGFRB fusion transcripts in a myeloproliferative neoplasm patient with t(5;17)(q32;q11)

Guangying Sheng1, Zhao Zeng1, Jinlan Pan1

  • 1Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, Jiangsu province 215006 China.

Abstract

Insights

A novel MYO18A-PDGFRB gene fusion was identified in a patient with myeloproliferative neoplasms (MPNs) lacking eosinophilia. Treatment with imatinib led to complete remission, suggesting this fusion is a targetable aberration in MPNs.

Area of Science:

  • Hematology
  • Molecular Biology
  • Genetics

Background:

  • Myeloproliferative neoplasms (MPNs) are characterized by myeloid proliferation, but rarely involve platelet-derived growth factor receptor beta (PDGFRB) rearrangements.
  • Eosinophilia is a common feature of MPNs, but its absence does not exclude the disease.

Observation:

  • A unique MPN case lacking eosinophilia presented with a novel PDGFRB rearrangement, specifically a t(5;17) translocation.
  • Fluorescence in situ hybridization (FISH) confirmed PDGFRB gene translocation to 5q31-q33.
  • RNA sequencing identified a previously undescribed MYO18A-PDGFRB gene fusion with a novel breakpoint (exon 37 of MYO18A and exon 13 of PDGFRB).

Findings:

  • RT-PCR and Sanger sequencing confirmed the out-of-frame MYO18A-PDGFRB fusion.
  • Multiple in-frame PDGFRB fusion transcripts were also identified.
  • Post-imatinib treatment, the t(5;17) translocation was undetectable by cytogenetics and FISH.

Implications:

  • The MYO18A-PDGFRB fusion represents a recurrent genetic aberration in MPNs.
  • Novel breakpoints in PDGFRB fusions expand our understanding of MPN pathogenesis.
  • Targeting the MYO18A-PDGFRB fusion with imatinib induced complete remission, highlighting its therapeutic potential in specific MPN subtypes.